Table 1.
Clinical characteristics of the whole cohort presented as mean±SD or percentages
| Basic characteristics | |
| N | 894 |
| Age (years) | 49.78±14.07 |
| Men (%) | 597 (66.8) |
| BMI (kg/m2) | 25.58±3.84 |
| WHR | 0.95±0.07 |
| SBP (mm Hg) | 134.78±18.32 |
| DBP (mm Hg) | 83.88±12.73 |
| Parent history of diabetes (%) | 132 (14.8) |
| Sibling history of diabetes (%) | 88 (9.8) |
| Drinking (%) | 240 (26.8) |
| Laboratory data | |
| Hb (g/L) | 137.60±19.84 |
| PLT (*109/L) | 219.75±88.10 |
| FBG (mmol/L) | 9.20±4.56 |
| HbA1c (%) | 10.13±2.8 |
| Alb (g/L) | 37.24±4.90 |
| TC (mmol/L) | 4.63±1.44 |
| LDL (mmol/L) | 2.87±1.02 |
| HDL (mmol/L) | 0.98±0.30 |
| TG (mmol/L) | 2.70±3.37 |
| sCre (µmol/L) | 68.45±38.07 |
| HOMA2-IR (%) | 1.44±1.34 |
| HOMA2-B (%) | 50.89±50.03 |
| Complications | |
| DKA | 35 (3.9) |
| HTN | 352 (39.4) |
| Medications | |
| ACEI (%) | 126 (14.1) |
| ARB (%) | 134 (15) |
| Lipid-lowering agents (%) | 564 (63.1) |
HOMA2-B and HOMA2-IR were applied to estimate the function of β-cell and insulin resistance, respectively, which were calculated using fasting plasma glucose and C-peptide.
ACEI, ACE inhibitor; Alb, albumin; ARB, angiotensin receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; DKA, diabetic keto acidosis; DM, diabetes mellitus; FBG, fasting blood glucose; Hb, haemoglobin; HbA1C, glycosylated haemoglobin; HDL, high-density lipoprotein; HOMA2-B, homoeostatic model assessment 2-B; HOMA2-IR, homoeostatic model assessment 2-insulin resistance; HTN, hypertension; LDL, low-density lipoprotein; PLT, platelet; SBP, systolic blood pressure; sCre, serum creatinine; TC, total cholesterol; TG, triglyceride; WHR, waist-to-hip ratio.